Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryAetna Age-Related Macular Degeneration Coverage | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0765

    Age-Related Macular Degeneration

    Customize your policy alerts

    Sign up for Aetna Policy 0765 alerts

    Get alerted when Policy 0765 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity criteria for therapies used to manage neovascular (wet) ARMD and specific coverage criteria for the implantable miniature telescope (IMT) in patients aged 65 and older; lists interventions considered experimental/investigational and associated billing codes within the portion of the policy provided.

    Policy Summary
    PayerAetna
    PolicyAge-Related Macular Degeneration
    Policy CodePolicy 0765
    Change TypeNo material change
    Effective Date
    Last ReviewFeb 20, 2024
    Next Review Date
    Key ActionDocument a >=5-letter ETDRS improvement with an external telescope, complete 2–4 pre-surgical training sessions, and document required pre-op testing and absence of contraindications prior to IMT implantation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical/coverage changes in this update (has_material_change=false).

    6Medically Necessary Therapies Listed
    30Experimental/Investigational Items Listed (approx.)
    5 lettersETDRS improvement threshold
    20/160-20/800Allowed binocular VA range
    2-4Required pre-surgical training sessions
    1IMT device post-approval studies mandated

    Coverage Summary

    Scope: This policy defines Aetna's medical necessity criteria for management of Age-Related Macular Degeneration (ARMD), including therapies for neovascular (wet) ARMD and specific selection, eligibility, and contraindication criteria for the Implantable Miniature Telescope (IMT) monocular implant in members aged 65 years and older (coverage limited to ages ≥ 65 years). Status: CURRENT. Subject: Age-Related Macular Degeneration (ARMD) treatments and Implantable Miniature Telescope (IMT).

    High-level coverage stance: Aetna's coverage is mixed. Medically necessary therapies listed for neovascular (wet) ARMD include aflibercept, bevacizumab, pegaptanib sodium, photodynamic therapy (PDT) with verteporfin, ranibizumab, and brolucizumab when criteria are met. The IMT is covered for monocular implantation when ALL specified pre-operative selection criteria and age/visual acuity thresholds are met. Numerous diagnostics and interventions (e.g., various genetic tests, home hyperacuity monitoring, microperimetry, AI-based detection, stem cell transplantation, complement inhibitors, photobiomodulation, gene therapy, epimacular brachytherapy, and others) are designated experimental and investigational because effectiveness has not been established.

    IMT high-level note: The IMT is an FDA-approved monocular intraocular telescope prosthesis for end-stage ARMD with bilateral central scotoma; coverage requires demonstration of pre-implantation improvement with an external telescope (at least a 5-letter ETDRS improvement), other pre-surgical tests/training, specified binocular visual acuity range (worse than 20/160 but not worse than 20/800 in both eyes), absence of active CNV, and fulfillment of device-specific anatomic and endothelial cell density thresholds.

    IMT key eligibility / threshold facts
    ETDRS external telescope improvement threshold
    Policy Summary
    PayerAetna
    PolicyAge-Related Macular Degeneration
    Policy CodePolicy 0765
    Change TypeNo material change
    Effective Date
    Last ReviewFeb 20, 2024
    Next Review Date
    Key ActionDocument a >=5-letter ETDRS improvement with an external telescope, complete 2–4 pre-surgical training sessions, and document required pre-op testing and absence of contraindications prior to IMT implantation.
    SourceLink
    On This Page
    Coverage SummaryMedical Necessity CriteriaExperimental and Not Covered Interventions & DiagnosticsCodingProvider Actions & Documentation RequirementsBackground & Evidence SummaryDefinitionsMedicare DeterminationsRevision History
    >= 5-letter improvement
    IMT age eligibility>= 65 years
    Pre-op binocular visual acuity rangeWorse than 20/160 and not worse than 20/800 in both eyes
    Pre-op IOP contraindication thresholdPre-op IOP > 22 mm Hg on maximum medication (device contraindicated)
    Axial length requirement (operative eye)>= 21 mm (operative eye must NOT be < 21 mm)
    Central anterior chamber depth (operative eye)>= 3.0 mm
    Endothelial cell density (ECD) minimumsAge 65–84: >= 2000 cells/mm2; Age >=85: >= 1800 cells/mm2

    Medical Necessity Criteria

    Medically Necessary Therapies for Neovascular (Wet) ARMD

    • Aflibercept (Eylea) injection
    • Bevacizumab (Avastin) injection
    • Pegaptanib sodium (Macugen) injection
    • Photodynamic therapy (PDT) with verteporfin
    • Ranibizumab (Lucentis) injection
    • Brolucizumab (Beovu) injection

    IMT (Implantable Miniature Telescope) - Medically Necessary / Coverage Criteria

    Covered when ALL of the following are met:

    • Member aged 65 years or older

      Age requirement for IMT

    • Monocular implantation planned for the worse-seeing eye with stable, untreatable, severe-to-profound central vision impairment (bilateral central scotoma) due to end-stage ARMD as confirmed by fluorescein angiography
    • Achieves at least a 5-letter improvement on the ETDRS visual acuity chart in the eye scheduled for surgery using an external telescope

      Demonstration of potential benefit pre-operatively

    • Adequate peripheral vision in the fellow (non-operative) eye to allow for orientation and mobility
    • Agreement to undergo 2 to 4 pre-surgical training sessions with a low vision specialist (optometrist or occupational therapist)
    • Presence of a visually significant cataract in the operative eye (grade 2 or higher)

    IMT - Contraindications

    • History of clinically significant steroid-induced intraocular pressure (IOP) elevation or steroid responder
    • Uncontrolled glaucoma (inadequately controlled despite therapy)
    • Compromised peripheral visual field in the intended operative eye sufficient to preclude functional use of the IMT
    • Active choroidal neovascularization (active wet ARMD) in either eye
    • Known sensitivity or allergy to device materials or required perioperative medications

    IMT coverage / candidate selection (Background section criteria)

    Background section criteria — candidate selection thresholds (duplicate/alternate brief summary of IMT coverage criteria):

    • Age 65 years or older
    • Monocular implantation for end-stage ARMD with bilateral central scotoma confirmed by fluorescein angiography
    • Pre-operative demonstration of at least a 5-letter ETDRS improvement using an external telescope in the eye to be implanted
    • Adequate peripheral vision in the fellow eye for orientation and mobility
    • Completion of 2 to 4 pre-surgical training sessions with a low vision specialist

    IMT contraindications (device is contraindicated if ANY of the following are present)

    Device is contraindicated if ANY of the following are present in the planned operative eye:

    Operative eye-specific exclusions (IMT not suitable if planned operative eye has ANY of the following)

    • Axial length outside device-specified range (insufficient or excessive axial length)
    • Shallow anterior chamber depth inadequate for device implantation
    • Endothelial cell density (ECD) below manufacturer-specified threshold
    • Active corneal disease or dystrophy (e.g., Fuchs endothelial dystrophy) that would compromise corneal health post-implantation
    • Significant posterior segment disease other than ARMD that would limit visual potential (e.g., advanced diabetic retinopathy, macular hole)

    Experimental and Not Covered Interventions & Diagnostics

    Not covered codes: The policy lists specific CPT, HCPCS, and ICD-10 code groups marked as not covered for the indications in this CPB, including CPT codes for experimental diagnostics and tests (e.g., 0378T, 0379T, 0506T, 0205U), additional CPT/other procedure codes noted in the policy listing (e.g., codes related to stem cell or radiation therapies), HCPCS/J-codes not covered (e.g., J3300, J3301, J9212–J9215, S2140, S2150, S9559), and ICD-10 ranges listed as not covered for the specified indications (e.g., H35.051–H35.059, H35.30, H35.3110–H35.3194).

    Coding

    CPT codes covered if selection criteria are metCPTCovered
    67028Intravitreal injection of a pharmacologic agent (separate procedure)
    67221Destruction of localized lesion of choroid (e.g., choroidal neovascularization); photodynamic therapy (includes intravenous infusion)
    67225Photodynamic therapy, second eye, at single session (List separately in addition to code for primary eye treatment)
    0308TInsertion of ocular telescope prosthesis including removal of crystalline lens or intraocular lens prosthesis
    CPT codes not covered for indications listed in the CPB / Experimental diagnostics and testsCPTNot Covered
    0378TVisual field assessment with remote surveillance (ForeseeHome device)
    0379TVisual field assessment technical support and surveillance (ForeseeHome device)
    0506TMacular pigment optical density measurement by heterochromatic flicker photometry
    0205UOphthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH, 1 ARMS2) PCR and MALDI-TOF
    38232Bone marrow harvesting for transplantation; autologous
    38240Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
    38241Autologous transplantation
    38242Allogeneic lymphocyte infusions
    77432Stereotactic radiation treatment management of cranial lesion(s) (one session)
    77520Proton treatment delivery; simple, without compensation
    1–10 of 15
    1/2
    HCPCS codes covered if selection criteria are met (drug/injection codes)HCPCSCovered
    C9161Injection, aflibercept hd, 1 mg
    C9257Injections, Bevacizumab, 0.25 mg
    J0178Injection, aflibercept, 1 mg
    J0179Injection, brolucizumab-dbll, 1 mg
    J2503Injection, pegaptanib sodium, 0.3 mg
    J2778Injection, ranibizumab, 0.1 mg
    J3396Injection, verteporfin, 0.1 mg
    J9035Injection, bevacizumab, 10 mg
    Q5107Injection, bevacizumab-awwb (mvasi), 10 mg
    HCPCS codes not covered for indications listed in the CPBHCPCSNot Covered
    J3300Injection, triamcinolone acetonide, preservative free, 1 mg
    J3301Injection, triamcinolone acetonide, per 10 mg
    J9212Injection, interferon alfacon-1, recombinant, 1 mcg
    J9213Interferon alfa-2A, recombinant, 3 million units
    J9214Interferon alfa-2B, recombinant, 1 million units
    J9215Interferon alfa-N3, 250,000 IU
    S2140Cord blood-derived stem cell transplantations, allogenic
    S2150Bone marrow or blood-derived stem cells harvesting/transplantation and related services
    S9559Home injectable therapy; interferon, per diem
    ICD-10 codes covered if selection criteria are metICD-10Covered
    H35.3210 - H35.3293Exudative age-related macular degeneration
    H35.31Nonexudative age-related macular degeneration
    H35.32Exudative senile macular degeneration
    H53.413Scotoma involving central area, bilateral
    ICD-10 codes not covered for indications listed in the CPBICD-10Not Covered
    H35.051 - H35.059Retinal neovascularization, unspecified [associated with age-related macular degeneration]
    H35.30Unspecified macular degeneration [age-related]
    H35.3110 - H35.3194Nonexudative age-related macular degeneration (range) - listed as not covered for indications in CPB

    Provider Actions & Documentation Requirements

    Documentation Required

    Documentation Requirements

    Providers must document required pre-surgical training and testing before IMT implantation. Record completion of 2–4 pre-surgical training sessions with a low-vision specialist (optometrist or occupational therapist) and participation/willingness to complete a post-operative visual rehabilitation program. Document the external ETDRS telescope test demonstrating an >= 5-letter improvement in the eye scheduled for surgery, evidence of adequate peripheral vision in the fellow eye for orientation and mobility, and evidence of a visually significant cataract (grade 2 or higher). Document absence of active choroidal neovascularization (CNV) in either eye by fluorescein angiography and no treatment for wet ARMD in the prior 6 months. If contraindications exist (e.g., uncontrolled glaucoma, other active eye disease), document the specific contraindication and supporting clinical data. Note manufacturer post-approval study follow-up requirements and include documentation of enrollment or agreement to participate when applicable.

    • Pre-surgical training completion: 2–4 sessions with low-vision specialist (document dates, provider, and summary of training).
    • ETDRS external telescope test: document >= 5-letter improvement on ETDRS chart in operative eye.
    • Fellow eye peripheral vision: document adequate peripheral vision for orientation/mobility (perimeter/visual field report).
    • Cataract evidence: document visually significant cataract (grade ≥2) in operative eye.
    • Fluorescein angiography: document end-stage ARMD and absence of active CNV in either eye.
    • No wet ARMD treatment in prior 6 months: document treatment history.
    • Visual acuity thresholds: document binocular VA poorer than 20/160 but not worse than 20/800.
    • Post-operative rehabilitation: signed plan/agreement to participate in post-op visual rehab.
    • Contraindication documentation: if any exclusion applies (e.g., uncontrolled glaucoma, other retinal disease), provide clinical evidence.
    • Manufacturer post-approval study: document enrollment or acknowledgement of follow-up requirements if IMT device manufacturer requires post-market surveillance.
    Billing Rule

    Billing & Coding Rules

    Billing rules and specific CPT reporting requirements for procedures related to IMT and intravitreal injections.

    • Report CPT 0308T for insertion of the implantable miniature telescope (IMT) when all IMT coverage criteria are met.
    • Report CPT 67028 for intravitreal injection of a pharmacologic agent (separate procedure) when intravitreal injections are performed per ARMD treatment protocols.
    Prior Authorization

    Prior Authorization & Pre-surgical Testing

    Prior authorization and pre-surgical testing requirements must be satisfied and documented before proceeding with IMT implantation. Provide objective test results and training documentation as part of the authorization package. Note manufacturer-required post-approval study follow-up and include any enrollment documentation.

    • Prior authorization: submit documentation of ETDRS external telescope test showing >=5-letter improvement, visual field/peripheral vision testing for fellow eye, cataract grade (≥2), fluorescein angiography confirming end-stage ARMD and absence of CNV, and clinical history showing no wet ARMD treatment in previous 6 months.
    • Pre-surgical measurements: document axial length, anterior chamber depth, and endothelial cell density (ECD) meeting manufacturer-specified thresholds prior to IMT implantation.
    • Pre-surgical training: evidence of completion of 2–4 training sessions with a low-vision specialist (dates and provider notes required).
    • Post-approval study: include manufacturer post-market study follow-up plan or documentation of patient agreement to participate if applicable.
    • Genetic testing and biomarkers: genetic testing for AMD (e.g., CFH, ARMS2 variants) is not required for IMT coverage and many genotype tests are considered investigational; if genetic/biomarker or AI-derived findings are used in clinical decision-making, include method, test name, and interpretation in the record.
    • OCT biomarkers and AI: document any optical coherence tomography (OCT) biomarker findings used to manage ARMD and note if artificial intelligence–based diagnostic support was consulted; include version, vendor, and report output when relied upon for clinical decisions.

    Background & Evidence Summary

    Background: ARMD is a progressive degenerative disease of the macula and a leading cause of blindness in developed countries, primarily affecting people aged 60 years and older; risk increases with age and certain exposures (e.g., heavy alcohol use). The disease spectrum includes early (few medium drusen or pigmentary changes), intermediate (large drusen or geographic atrophy not involving the center), and late/advanced ARMD which may be non-exudative (dry, atrophic) or neovascular/exudative (wet).

    Dry vs wet ARMD: The non-neovascular (dry) form causes slow, progressive macular deterioration with drusen and geographic atrophy. The neovascular (wet) form involves development of choroidal neovascularization (CNV) with leakage of blood and fluid, serous or hemorrhagic retinal pigment epithelial detachments, and scar formation, accounting for most cases of severe vision loss. Approximately 10–20% of patients with non-exudative ARMD progress to the exudative form.

    Risk factors and natural history: ARMD risk rises with age; environmental and genetic factors contribute. Dry ARMD gradually worsens over years, while conversion to wet ARMD with CNV can cause rapid central vision loss.

    Evolution of treatments: Historically, argon laser photocoagulation and submacular surgery were used but have limited roles due to harm or lack of benefit. Photodynamic therapy (PDT) with verteporfin limited visual loss in wet ARMD but typically does not improve vision. The advent of intravitreal anti-VEGF pharmacotherapies (pegaptanib, ranibizumab, bevacizumab, aflibercept, brolucizumab, and newer agents like faricimab) transformed management of neovascular ARMD, substantially reducing VA loss and providing VA gains with appropriate dosing regimens (e.g., VIEW trials for aflibercept; CATT comparing ranibizumab and bevacizumab).

    Emerging and surgical options: For patients with refractory/end-stage central vision loss, intra-ocular devices such as the Implantable Miniature Telescope (IMT) have been developed and FDA-approved for selected older patients; IMT clinical trials (IMT-002 and follow-ups) demonstrated VA and quality-of-life improvements but also notable endothelial cell loss and potential corneal complications, informing strict selection and follow-up criteria.

    Study/LabelKey finding/value
    IMT-002 trial endpoints
    90% met or exceeded improvement of ≥2 lines (1 year); NEI VFQ-25 QoL improved >7 points on 7 of 8 subscales; mean ECD loss 20% at 3 months and 25% at 12 months
    CATT trial
    Ranibizumab and bevacizumab had similar VA effects at 2 years; monthly dosing yielded greater gains than as‑needed
    AREDS2
    Addition of lutein+zeaxanthin or DHA+EPA to AREDS formulation did not significantly reduce progression to advanced ARMD (5‑year primary analyses)
    ForeseeHome HOME study
    Device arm had smaller decline in VA at CNV detection (median −4 letters) vs standard care (median −9 letters); p=0.021; earlier CNV detection
    EMBT RCT (CABERNET)
    At 24 months, 77% EMBT vs 90% control lost <15 letters; did not meet 10% non‑inferiority margin; mean VA change −2.5 letters (EMBT) vs +4.4 (control)
    Complement inhibitor trials
    Mixed results: lampalizumab negative; pegcetacoplan reduced GA lesion growth (monthly −0.38 mm²) but no BCVA benefit and possible increased MNV risk; avacincaptad pegol probably reduced GA growth; endophthalmitis risk small but increased
    Faricimab TENAYA/LUCERNE
    Faricimab non‑inferior to aflibercept for BCVA with potential for extended dosing up to 16 weeks; comparable ocular AEs
    Stem cell safety signals
    Case series of intravitreal autologous adipose‑derived stem cells (3 patients) with severe bilateral vision loss and serious ocular AEs; systematic reviews show small studies with incomplete AE reporting
    Select quantitative evidence metrics
    IMT-002 1-year VA endpoint90% met or exceeded >=2-line (10+ letter) improvement in near or distance BCVA at 1 year
    IMT mean ECD loss~20% at 3 months; ~25% at 12 months
    Deep learning (DL) pooled diagnostic metricsSensitivity 94%; Specificity 97%; AUC 0.9925; PLR 21.77; NLR 0.06; DOR 342.41
    Number of articles in OCT/biomarker systematic review90 articles reviewed
    Number of OCT biomarkers evaluated / pertinent to nAMD progression9 biomarkers identified; 5 considered pertinent (IRF, SHRM, drusen, ORT, HF)

    Definitions

    IMT: Implantable Miniature Telescope — a monocular intraocular telescope prosthesis for end-stage ARMD with central scotoma.

    ETDRS: Early Treatment Diabetic Retinopathy Study visual acuity chart.

    CNV: Choroidal neovascularization — pathologic new blood vessel growth beneath the retina responsible for neovascular (wet) ARMD.

    ECD: Endothelial cell density (cells/mm2) — corneal endothelial cell count used to assess suitability for IMT implantation.

    AREDS2: Age-Related Eye Disease Study 2 — major randomized trial evaluating nutritional supplementation for ARMD.

    GA: Geographic atrophy — an advanced atrophic form of AMD (non-exudative).

    MNV / CNV: Macular neovascularization / choroidal neovascularization (neovascular or 'wet' AMD).

    IRF: Intra-retinal fluid.

    SHRM: Subretinal hyperreflective material.

    ORT: Outer retinal tubulation.

    HF: Hyperreflective foci.

    NLR: Neutrophil-to-lymphocyte ratio — defined as neutrophil count divided by lymphocyte count.

    AREDS formulation: Antioxidant and zinc supplement formulation used in AREDS trials; AREDS2 formulation includes lutein/zeaxanthin and 80 mg zinc oxide.

    Medicare Determinations

    Name / LCDEffective / Status
    L37035 Vita Risk pharmacogenetic test for dry AMD (MoIDX: Vita Risk)
    retired 2017-07-10

    Revision History

    retired 2017-07-10Medicare LCD retirementLatest

    Medicare Local Coverage Determination L37035 for the Vita Risk pharmacogenetic test for dry AMD (MoIDX: Vita Risk) was retired effective 2017-07-10.

  1. No active choroidal neovascularization (no active wet ARMD) in either eye
  2. No ocular disease other than well-controlled glaucoma
  3. No treatment for wet ARMD in either eye within the previous 6 months
  4. Best-corrected visual acuity in both eyes poorer than 20/160 but not worse than 20/800VA range: >20/800?

    Exact requirement: poorer than 20/160 but not worse than 20/800 in both eyes

  5. Willingness to participate in a post-operative visual rehabilitation program
  6. Visually significant cataract (grade 2 or higher) in the operative eye
  7. No active CNV (no active wet ARMD) in either eye
  8. Only well-controlled glaucoma (if present)
  9. No wet ARMD treatment in the previous 6 months
  10. Binocular visual acuity poorer than 20/160 but not worse than 20/800
  11. Agreement to participate in post-operative visual rehabilitation
  12. Insufficient capsular support or other anatomic contraindication to intraocular lens/device implantation
  13. Prior ocular surgery or ocular condition that, in the surgeon's judgment, precludes safe implantation or expected benefit from the IMT